Real-World data reveals treatment patterns for advanced prostate cancer
NCT ID NCT06072196
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study examined how long men with metastatic castration-sensitive prostate cancer take newer hormonal therapies like abiraterone, apalutamide, and enzalutamide. Researchers analyzed Medicare claims data from over 3,000 men aged 65 and older. The goal was to describe real-world treatment duration, not to test a new drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
abiraterone, apalutamide, enzalutamide
What this could lead to
If successful, this study could help doctors understand how long patients typically stay on these treatments, guiding better care decisions.
What could go wrong
This is an observational study using insurance claims, not a controlled trial. It cannot prove cause and effect, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer, Inc
New York, New York, 10001, United States